Comment from Timothy Hahn

Summary: Timothy Hahn, a patient's spouse, opposes the withdrawal of TAVNEOS approval because the medication significantly improved his wife's quality of life and health. He argues that the drug's risks (hepatotoxicity) appear to be specific to certain demographics and can be managed through enhanced monitoring and updated prescribing information rather than a total market withdrawal.